Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials
European Journal of Clinical Pharmacology · 2026
DOI: 10.1007/s00228-026-04186-5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Karollyna M Henry Moore und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fundación H. A. Barceló, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Helicobacter Infections, Helicobacter pylori, Lactobacillus. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Helicobacter pylori eradication therapies supplemented with Lactobacillus spp. may improve eradication rates and reduce adverse events by modulating gut microbiota and immune responses. This meta-analysis aimed to evaluate the efficacy and safety of Lactobacillus-supplemented Helicobacter pylori eradication therapy.
Methods
We systematically searched for randomized controlled trials (RCTs) comparing standard Helicobacter pylori eradication therapy with and without Lactobacillus in PubMed, Embase, and Cochrane Library up to August 2026. The primary outcome was eradication success, and the secondary outcome was adverse events. We calculated pooled risk ratios (RR) with 95% confidence intervals (CIs) using a random-effects model. We also estimated the number needed to treat (NNT) for eradication success and conducted subgroup analyses by antibiotic therapy type, duration of antibiotic treatment, Lactobacillus strain type, Lactobacillus dosage, period of Lactobacillus use, probiotic formulation, geographical region, and age range. This review was registered in PROSPERO (CRD42024611138).
Results
Thirty-two RCTs (4,010 patients) were included. Lactobacillus -supplemented eradication therapy improved eradication success (RR 1.10; 95%CI 1.05–1.14; NNT 13) and reduced the risk of adverse events (RR 0.70; 95%CI 0.58–0.84). Subgroup analyses showed significant differences in eradication success by antibiotic regimen and in adverse event risk by age group. Improved eradication success with Lactobacillus -supplemented eradication therapy was observed only with triple therapy regimens, whereas adverse event risk was reduced only among adults.
Conclusion
Lactobacillus -supplemented eradication therapy was associated with a 10% relative increase in Helicobacter pylori eradication success and a 30% relative reduction in treatment-related adverse events compared with the control group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fundación H. A. Barceló, Buenos Aires, Argentina.
- Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- University Center Christus, Fortaleza, Brazil.
- Department of Pediatric Gastroenterology, Jaraguá Hospital, Jaraguá do Sul, Brazil.
- Division of Gastroenterology, Department of Internal Medicine, Feevale University, Novo Hamburgo, Brazil. gilmara@feevale.br.
Zitieren
APA
Moore, K. M. H., Santo, P., Holanda, E. U., Nau, A. L., & Meine, G. C. (2026). Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04186-5
Vancouver
Moore KMH, Santo P, Holanda EU, Nau AL, Meine GC. Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04186-5
BibTeX
@article{Moore2026,
author = {Moore, Karollyna M Henry and Santo, Paula and Holanda, Erica Uchoa and Nau, Angélica Luciana and Meine, Gilmara Coelho},
title = {Effectiveness of Lactobacillus-supplemented eradication therapy for Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1007/s00228-026-04186-5}
}
EUVIMED